These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 17062694)
1. The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Hasegawa K; Nakamura T; Harvey M; Ikeda Y; Oberg A; Figini M; Canevari S; Hartmann LC; Peng KW Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6170-8. PubMed ID: 17062694 [TBL] [Abstract][Full Text] [Related]
2. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872 [TBL] [Abstract][Full Text] [Related]
3. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Anderson BD; Nakamura T; Russell SJ; Peng KW Cancer Res; 2004 Jul; 64(14):4919-26. PubMed ID: 15256464 [TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Peng KW; TenEyck CJ; Galanis E; Kalli KR; Hartmann LC; Russell SJ Cancer Res; 2002 Aug; 62(16):4656-62. PubMed ID: 12183422 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. Peng KW; Hadac EM; Anderson BD; Myers R; Harvey M; Greiner SM; Soeffker D; Federspiel MJ; Russell SJ Cancer Gene Ther; 2006 Aug; 13(8):732-8. PubMed ID: 16543921 [TBL] [Abstract][Full Text] [Related]
6. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484 [TBL] [Abstract][Full Text] [Related]
7. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Allen C; Vongpunsawad S; Nakamura T; James CD; Schroeder M; Cattaneo R; Giannini C; Krempski J; Peng KW; Goble JM; Uhm JH; Russell SJ; Galanis E Cancer Res; 2006 Dec; 66(24):11840-50. PubMed ID: 17178881 [TBL] [Abstract][Full Text] [Related]
8. Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. Myers R; Greiner S; Harvey M; Soeffker D; Frenzke M; Abraham K; Shaw A; Rozenblatt S; Federspiel MJ; Russell SJ; Peng KW Cancer Gene Ther; 2005 Jul; 12(7):593-9. PubMed ID: 15746945 [TBL] [Abstract][Full Text] [Related]
9. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. Melani C; Figini M; Nicosia D; Luison E; Ramakrishna V; Casorati G; Parmiani G; Eshhar Z; Canevari S; Colombo MP Cancer Res; 1998 Sep; 58(18):4146-54. PubMed ID: 9751627 [TBL] [Abstract][Full Text] [Related]
10. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Gauvrit A; Brandler S; Sapede-Peroz C; Boisgerault N; Tangy F; Gregoire M Cancer Res; 2008 Jun; 68(12):4882-92. PubMed ID: 18559536 [TBL] [Abstract][Full Text] [Related]
11. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196 [TBL] [Abstract][Full Text] [Related]
12. Measles virus: immunomodulation and cell tropism as pathogenicity determinants. Schneider-Schaulies S; Schneider-Schaulies J; Niewiesk S; Ter Meulen V Med Microbiol Immunol; 2002 Oct; 191(2):83-7. PubMed ID: 12410346 [TBL] [Abstract][Full Text] [Related]
13. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Liu C; Hasegawa K; Russell SJ; Sadelain M; Peng KW Prostate; 2009 Jul; 69(10):1128-41. PubMed ID: 19367568 [TBL] [Abstract][Full Text] [Related]
14. Rescue and propagation of fully retargeted oncolytic measles viruses. Nakamura T; Peng KW; Harvey M; Greiner S; Lorimer IA; James CD; Russell SJ Nat Biotechnol; 2005 Feb; 23(2):209-14. PubMed ID: 15685166 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248 [TBL] [Abstract][Full Text] [Related]
16. Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Figini M; Ferri R; Mezzanzanica D; Bagnoli M; Luison E; Miotti S; Canevari S Gene Ther; 2003 Jun; 10(12):1018-25. PubMed ID: 12776159 [TBL] [Abstract][Full Text] [Related]
17. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Springfeld C; von Messling V; Frenzke M; Ungerechts G; Buchholz CJ; Cattaneo R Cancer Res; 2006 Aug; 66(15):7694-700. PubMed ID: 16885371 [TBL] [Abstract][Full Text] [Related]
18. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Ong HT; Timm MM; Greipp PR; Witzig TE; Dispenzieri A; Russell SJ; Peng KW Exp Hematol; 2006 Jun; 34(6):713-20. PubMed ID: 16728275 [TBL] [Abstract][Full Text] [Related]
19. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. Knutson KL; Krco CJ; Erskine CL; Goodman K; Kelemen LE; Wettstein PJ; Low PS; Hartmann LC; Kalli KR J Clin Oncol; 2006 Sep; 24(26):4254-61. PubMed ID: 16908932 [TBL] [Abstract][Full Text] [Related]
20. Evidence for nonspecific adsorption of targeted retrovirus vector particles to cells. Pizzato M; Blair ED; Fling M; Kopf J; Tomassetti A; Weiss RA; Takeuchi Y Gene Ther; 2001 Jul; 8(14):1088-96. PubMed ID: 11526456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]